Αποτελέσματα Αναζήτησης
Objective: The relationship between cancers and obstructive sleep apnea (OSA) has been discussed for decades. However, the previous meta-analysis led to opposite conclusions. To further investigate this controversial issue, we performed this systematic review and meta-analysis update. Methods:
21 Σεπ 2022 · We aimed to study the effect of obstructive sleep apnea (OSA) on cancer risk. We searched PubMed, Embase, and Cochrane databases for relevant studies. The qualities of included studies were assessed using Newcastle–Ottawa Scale (NOS). Unadjusted and adjusted analyses were performed.
18 Ιαν 2024 · Sleep disorders such as sleep-disordered breathing (eg, obstructive sleep apnea), and other sleep disturbances, as well, some of which are also considered sleep disorders (eg, insomnia, sleep fragmentation, circadian rhythm disorders, and extreme sleep duration), have been associated with adverse brain health.
Sleep fragmentation participates in increasing cancer risk. Modulating effects of age remain controversial. Summary: Effects of OSA on cancer may largely vary among neoplastic diseases, both in their magnitude and direction.
With rising awareness of OSA and the increasing prevalence of obesity, OSA is increasingly recognized as a major contributor to cardiovascular morbidity including systemic and pulmonary arterial hypertension, heart failure, acute coronary syndromes, atrial fibrillation, and other arrhythmias.
4 Μαΐ 2024 · Our MR provided important insights into the causal associations between OSA and cancer risk, highlighting both protective and potentially harmful effects of OSA on different cancer types. Observational studies have suggested that obstructive sleep apnea (OSA) may have a potential carcinogenic role.
22 Σεπ 2022 · In the unadjusted analysis, we discovered an increased cancer risk in patients with OSA with a pooled relative risk (RR) in the OSA group of 1.49 (95% confidence interval (CI): 1.32-1.69, I 2 = 32%, P = 0.15). In adjusted analysis, OSA correlated with cancer risk (RR: 1.36, 95% CI: 1.18-1.56, I 2 = 54%, P < 0.01).
